BRKR earnings call summary

Prepared Highlights

• Q4 2025 reported revenue $977.2M, approximately flat YoY; organic decline 5.1%, M&A contribution 0.8%, currency tailwind 4.1% (prepared)
• Full-year 2025 reported revenue $3.44B, +2.1% YoY; organic decline 3.7%, M&A +3.5%, currency tailwind 2.3% (prepared)
• Q4 2025 non-GAAP operating margin 15.7%, down 240 bps YoY; full-year non-GAAP operating margin 12.6%, down 280 bps YoY (prepared)
• Q4 2025 non-GAAP diluted EPS $0.59, down 22.4% YoY; full-year non-GAAP EPS not explicitly stated in prepared remarks (prepared)
• Q4 2025 free cash flow $207.3M, up ~$54M YoY; full-year operating cash flow Q4 highest in history at ~$230M (CFO)
• BSI book-to-bill >1.0x for Q4 2025, second consecutive quarter (CEO)
• BSI backlog ~7 months of revenue entering 2026 (CEO)
• BEST segment secured multiyear agreements worth >$500M for superconducting wire; research instruments received >$40M in orders for extreme light infrastructure (CEO)
• BSI aftermarket revenue 38% of segment revenue in 2025, up from 35% in 2024 (CEO)
• China revenue declined to just under 14% of total revenue in 2025, from 16-17% previously (CEO)
• Leverage ratio ~3.1% at end of FY2025 (CFO)

Official Guidance (FY2026):

• Reported revenue $3.57B–$3.60B, +4%–5% YoY; organic revenue growth 1%–2%; M&A contribution 1.5%; currency tailwind 1.5% (CEO, CFO)
• Non-GAAP operating margin expansion 250–300 bps (including ~50 bps currency headwind); organic expansion 300–350 bps (CFO)
• Non-GAAP EPS $2.10–$2.15, +15%–17% YoY; CER EPS growth 23%–25% (CFO)
• Q1 2026: organic revenue down mid-single digits; operating margin and EPS down meaningfully YoY; organic growth expected to resume in Q2 2026 (CFO)

Mgmt Quotes:

• "We are pleased that in the fourth quarter, we delivered revenues ahead of our expectations." (CEO)
• "We start the year with solid BSI segment backlog of over 7 months of revenue and good bookings momentum." (CEO)
• "We remain very committed to rapid non-GAAP operating profit margin expansion, and we aim for 250 to 300 bps operating profit margin improvement in '26." (CEO)
• "We had an excellent cash generation quarter in the fourth quarter of '25 with approximately $230 million of operating cash flow generated in the quarter, actually the highest in our history." (CFO)
• "We expect to take a major step up in operating margin performance in fiscal year '26 with much of this margin improvement driven by our previously announced 120 million cost actions." (CFO)

Prepared Metrics

Q&A Batch (1-5 of 7)

Q1 — Puneet Souda

• Topic: 2026 margin drivers, cost initiatives, and Q1 margin cadence
• Key points:
  • Q4 2025 margin 100 bps below expectation: 50 bps from unfavorable mix (idiosyncratic, not repeating), 30 bps from late tariff offset (to be offset in 2026), 20 bps from stronger currency headwind (persistent).
  • Annualized cost savings now expected closer to $140 million or higher (previously $100–$120 million), additional 10%–15% push; fully effective by Q3 2026.
  • Q1 2026 organic revenue expected softer (mid-single-digit decline), with ramp starting Q2; Q1 2025 was strong (mid-single-digit BSI organic growth).
• Mgmt stance: Bullish on margin expansion — cost actions expanded, idiosyncratic mix not repeating, tariff offset planned; cautious on Q1 revenue due to comps and still-weak U.S. ACA/GOV orders.

Q2 — Michael Ryskin

• Topic: Confidence in 2026 margin execution and revenue pacing through year
• Key points:
  • $100–$120 million cost savings already taken; additional costs becoming fully effective by midyear 2026.
  • Q1 2026 organic revenue down mid-single digits; comps ease significantly from Q2 2025 (which was weak), enabling positive growth in remaining quarters.
  • Order momentum improving in biopharma, semi, China; U.S. ACA/GOV still weak but may benefit bookings in H2 2026, revenue impact likely Q4 2026 or 2027.
• Mgmt stance: Bullish on margin execution — cost actions and pricing/supply chain improvements with longer lead times give confidence; neutral on near-term revenue — gradual improvement, not yet back to long-term growth rates (target 200–300 bps above market organic CAGR in 2027+).

Q3 — Tycho Peterson

• Topic: End-market assumptions for 2026 and gross margin outlook
• Key points:
  • End-market assumptions: biopharma low single-digit organic growth (no snapback); semi low single-digit growth; clinical (microbiology) stronger; academic/government flat to low single-digit down; industrial flat; applied flat.
  • Molecular diagnostics: ~30% more Genius platform placements in 2025 than planned, driving pull-through in 2026.
  • Operating profit margin expansion ~half from gross margin expansion, half from OpEx; gross margin expected to expand in 2026 (mix improvement, tariff mitigation).
• Mgmt stance: Bullish on diagnostics and semi as highlights; neutral on overall growth — no significant snapback assumed; confident in gross margin expansion via mix and tariff recovery.

Q4 — Subhalaxmi Nambi

• Topic: Book-to-bill trends and product roadmap for microbiology/diagnostics
• Key points:
  • BSI book-to-bill above 1.0 in last two quarters; expected to continue in 2026 aided by easier comps; backlog may be used but not normalized to ~5 months level.
  • Microbiology: first rapid AST gram-negative/positive blood culture claim FDA approval expected before mid-2026; additional claims in clinical trials; WAVE platform buildup over next few years.
  • Diagnostics (Genius): first U.S. assay entering clinical trials in 2026, revenue impact in 2027+; syndromic panels rolling out in Europe late 2026/2027; molecular diagnostics was mid- to high single-digit growth market in 2025.
• Mgmt stance: Bullish on long-term product pipeline — cumulative effect of new platforms and claims; neutral on 2026 revenue impact — investments continue, meaningful growth from 2027 onward.

Q5 — Douglas Schenkel

• Topic: Q1 2026 organic revenue guidance vs. discrete positive items (semi, pricing, NMR)
• Key points:
  • Q1 2025 had strong semi orders and bookings, creating a headwind for Q1 2026 comps.
  • Semi orders pushed out of Q4 2025 expected to be recaptured in H1 2026, not all in Q1.
  • No specific NMR pushout; 1.2 GHz NMR was delivered in Q4 2025 (U.K.).
  • Mid-single-digit Q1 organic decline is the right number; subsequent three quarters expected to show more meaningful growth.
• Mgmt stance: Neutral/cautious on Q1 — timing of orders and strong prior-year comps outweigh discrete positive items; bullish on rest of year — organic growth resumes from Q2.

Q&A Batch (6-7 of 7)

Q6 — Jake (on for Luke)

• Topic: China end-market mix and 2026 outlook
• Key points:
  • China CRO business recovered after a lull; biopharma piece is growing noticeably; academic spending and bookings in Q4 were better than prior year.
  • China was one of the better performers in Q4 bookings and had decent revenues at year-end, but trends are hard to read.
  • APAC (India, Korea, Taiwan, Japan) also shows improving biopharma trends; semiconductor metrology benefits orders in APAC outside China.
• Mgmt stance: Neutral — China guide for 2026 assumes largely flat revenue, not a snapback; Gerald Herman explicitly said "not strong."

Q7 — Daniel Brennan

• Topic: U.S. academic/government (ACA/GOV) trends, semis outlook, and segment growth
• Key points:
  • U.S. ACA/GOV bookings for full year 2025 were down in the high teens; some quarters down more than 20%.
  • 2026 guide expects U.S. ACA/GOV revenue to be down organically; global ACA/GOV guide is not expecting significant growth.
  • Semis: full year 2025 revenue was flat; 2026 guide expects low single-digit growth.
  • BioSpin expected to be the weakest growth segment in 2026; B Nano, CALID, and BEST all expected to grow organically at comparable rates.
  • Ultra-high field NMR: only one installation expected in 2026; hopes to return to 2–3 installations per year by 2027.
• Mgmt stance: Cautious on ACA/GOV (continued headwind); neutral on semis (modest recovery); cautious on BioSpin (laggard due to long-cycle bookings and ultra-high field lull).

Q8 — Brandon Couillard

• Topic: Segment growth leaders, ultra-high field NMR, interest expense, and free cash flow
• Key points:
  • BioSpin will be the laggard in 2026 revenue growth; B Nano, CALID, and BEST will all grow organically at comparable rates.
  • Ultra-high field NMR: expects 2–3 installations per year by 2027 (down from prior 4 per year).
  • Q4 free cash flow was $207 million, driven by working capital and inventory actions.
  • 2026 interest expense guided to $35–$40 million range; other income line expected to improve net interest/other income performance.
• Mgmt stance: Neutral on segment mix (BioSpin weak, others growing); bullish on cash flow (pleased with Q4 conversion and inventory progress).